Oxford Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Oxford Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,358	Closed	-$101K	–	379
2023 Q4	$101K	Buy	+19,358	New	+$191K	0.15%	160
2020 Q1	–	Sell	-10,873	Closed	-$653K	–	1401
2019 Q4	$653K	Sell	10,873 -21,012	-66%	-$1.25M	0.02%	1096
2019 Q3	$1.8M	Sell	31,885 -27,831	-47%	-$1.57M	0.04%	610
2019 Q2	$3.33M	Buy	+59,716	New	+$3.11M	0.07%	413
2018 Q4	–	Sell	-40,852	Closed	-$2.83M	–	2168
2018 Q3	$2.83M	Buy	+40,852	New	+$3.1M	0.06%	470
2018 Q2	–	Sell	-5,296	Closed	-$279K	–	1975
2018 Q1	$279K	Sell	5,296 -56,399	-91%	-$3.28M	0.01%	1423
2017 Q4	$3.31M	Buy	61,695 +36,331	+143%	+$2.02M	0.07%	338
2017 Q3	$1.51M	Buy	25,364 +14,810	+140%	+$896K	0.03%	761
2017 Q2	$833K	Sell	10,554 -8,241	-44%	-$674K	0.02%	946
2017 Q1	$1.56M	Buy	+18,795	New	+$1.4M	0.04%	609

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Oxford Asset Management's EGRX Position: Q1 2024 in Review

Oxford Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 19,358 shares — an estimated $101K sold.

Oxford Asset Management first reported a position in EGRX in Q1 2017 and held it in 10 quarters. The position peaked at $3.33M in Q2 2019. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

Oxford Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Oxford Asset Management sold 19,358 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $101K.
Oxford Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 10 quarters.
Oxford Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $3.33M in Q2 2019.
91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Oxford Asset Management's 13F filing for Q1 2024, filed 15 May 2024.